image: Injection of active p70 S6K1 virus into mediobasal hypothalamus reduces overeating of high fat diets and obesity. view more
Credit: Albert Einstein College of Medicine
December 10, 2008 - (BRONX, NY) - Researchers at Albert Einstein College of Medicine of Yeshiva University have found that overactivity of a brain enzyme may play a role in preventing weight gain and obesity. The findings were reported in Cell Metabolism.
To understand what drives hunger and causes metabolic disease, many scientists have focused on the hypothalamus, an almond-sized structure located deep within the brain that controls body temperature, hunger, and thirst. Specialized nerve cells in the hypothalamus sense whether the body contains adequate amounts of nutrients and stored body fat. The cells then send out signals telling other parts of the brain to adjust food intake, metabolic rates, and physical activity accordingly — keeping the body's caloric intake in balance with calories burned.
To learn more about these nutrient-sensing pathways and how they go awry in metabolic disorders, researchers at Einstein focused on an enzyme called p70 S6 Kinase 1, or S6K, which plays a role in regulating the growth and proliferation of all cells, including nerve cells.
"It turns out that this enzyme, and the pathway it regulates, is nutrient sensitive — that is, S6K activity increases in the presence of carbohydrates and protein," says the study's principal investigator, Gary J. Schwartz, Ph.D., professor of medicine and neuroscience at Einstein. "This led us to believe that S6K might not only be involved in maintaining the structure and function of individual cells, but also in regulating the energy balance of the whole body."
To test this hypothesis, the researchers injected rats with special viruses that selectively raise or lower S6K activity. The viruses were injected directly into the lower-middle, or mediobasal, portion of the hypothalamus, an area rich in nutrient-sensing nerve cells.
"When we raised the activity of the enzyme, we saw reductions in food intake, in body weight, and in production of peptides [small chains of amino acids] that normally stimulate feeding," says Dr. Schwartz. "When we lowered S6K activity, we saw essentially the opposite response."
The way increased S6K activity reduced the rats' food intake is important, says Dr. Schwartz: reducing the average size of meals rather than changing the number of meals over the course of a day. So the animals apparently were sated faster and therefore ate less at every meal.
In another experiment, the researchers tested whether increased S6K activity would protect against the natural tendency of mammals on a high-fat diet to overeat. People deal with all those calories by putting on extra weight and becoming insensitive to insulin — two of the hallmarks of metabolic syndrome, a group of risk factors that raise the risk of heart disease and type 2 diabetes.
When animals on a high-fat diet were given the S6K-enhancing virus, they overate less and gained weight more slowly than control animals, the researchers report. In addition, the virus-enhanced animals had lower body-fat levels and better glucose tolerance than the control group.
Overall, the study shows that S6K acts as a kind of food-sensing thermostat in mammals, increasing or decreasing feeding behavior and metabolism to maintain a normal energy balance. "These findings show that it may be possible to control obesity and other human metabolic disorders by developing drugs that regulate S6K activity," says Dr. Schwartz.
Clémence Blouet, Ph.D., a postdoctoral fellow at Einstein, is the lead author of the paper. The other co-author is Hiraku Ono, Ph.D., also a postdoctoral fellow at Einstein.
About Albert Einstein College of Medicine of Yeshiva University
Albert Einstein College of Medicine of Yeshiva University is one of the nation's premier centers for research, medical education and clinical investigation. It is the home to some 2,000 faculty members, 750 M.D. students, 350 Ph.D. students (including 125 in combined M.D./Ph.D. programs) and 380 postdoctoral investigators. Last year, Einstein received more than $130 million in support from the NIH. This includes the funding of major research centers at Einstein in diabetes, cancer, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Through its extensive affiliation network involving five hospital centers in the Bronx, Manhattan and Long Island – which includes Montefiore Medical Center, Einstein's officially designated University Hospital – the College runs one of the largest post-graduate medical training program in the United States, offering approximately 150 residency programs to more than 2,500 physicians in training. For more information, please visit www.aecom.yu.edu.
Journal
Cell Metabolism